# Advisor Review - GPT-5.4 (R2)

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5.4
**Paper:** paper.pdf
**Timestamp:** 2026-03-10T13:15:02.849686
**Route:** OpenRouter + LaTeX
**Paper Hash:** 62001d17cd8606bf
**Tokens:** 20223 in / 2994 out
**Response SHA256:** c507de6b0425f3e8

---

FATAL ERROR 1: Completeness  
  Location: Table “Callaway-Sant'Anna Aggregate Treatment Effects” (\label{tab:cs_results}), Results section  
  Error: This results table reports ATT estimates and SEs but does not report the sample size/observation count. Under your stated reporting standard, regression/estimation tables must include N. As written, a reader cannot tell whether the C-S estimates use the same 1,189 / 984 observations as the TWFE tables or a reduced estimation sample.  
  Fix: Add the estimation sample size to the table (e.g., observations, countries, periods used, and if relevant the number of treated cohorts contributing to each outcome).

FATAL ERROR 2: Completeness  
  Location: Appendix D, “Additional Heterogeneity Dimensions”  
  Error: The paper states results for three additional heterogeneity analyses (“By transposition speed,” “By baseline competition level,” and “By procurement volume”) but provides no table, figure, coefficients, standard errors, confidence intervals, or sample sizes for them. This is an incomplete analysis: analyses are described as done, but the results are not actually reported.  
  Fix: Either remove these claims entirely or add a table/figure reporting the estimates, SEs/CIs, and sample sizes for each heterogeneity split.

FATAL ERROR 3: Internal Consistency  
  Location: Appendix A, “Sample Construction”  
  Error: The accounting of the panel structure is internally inconsistent. The appendix says UK observations “post-2020 ... are excluded,” but then defines the balanced panel as \(28 \times 60 = 1{,}680\) cells and explains the 491 missing cells only by (a) Croatia pre-accession absence, (b) zero-award quarters in small states, and (c) reduced TED coverage in 2009–2010. The deliberate UK exclusion after 2020 is not included in that accounting, so the stated decomposition of missing cells is incomplete/inconsistent with the sample definition.  
  Fix: Reconcile the panel accounting explicitly. Either (i) redefine the balanced panel to reflect the UK exclusion, or (ii) keep the 28×60 benchmark but explicitly list post-2020 UK exclusion among the sources of missing cells and ensure the missing-cell count adds up under the stated sample rules.

ADVISOR VERDICT: FAIL